Investment Analysts’ Updated EPS Estimates for September 29th (CFR, CRNX, KALA, MBLY, MIR, MLTX, PNC, RKT, ST, SYF)

Investment Analysts’ updated eps estimates for Monday, September 29th:

Cullen/Frost Bankers (NYSE:CFR) had its price target increased by Morgan Stanley from $125.00 to $136.00. The firm currently has an underweight rating on the stock.

Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target increased by Morgan Stanley from $65.00 to $77.00. Morgan Stanley currently has an overweight rating on the stock.

KALA BIO (NASDAQ:KALA) had its neutral rating reaffirmed by analysts at HC Wainwright.

Mobileye Global (NASDAQ:MBLY) had its price target trimmed by The Goldman Sachs Group, Inc. from $19.00 to $16.00. They currently have a neutral rating on the stock.

Mirion Technologies (NYSE:MIR) had its price target increased by Northland Securities from $26.00 to $29.00. They currently have an outperform rating on the stock.

MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded by analysts at Jefferies Financial Group Inc. from a buy rating to a hold rating. Jefferies Financial Group Inc. currently has $8.00 target price on the stock.

The PNC Financial Services Group (NYSE:PNC) had its target price increased by Morgan Stanley from $186.00 to $206.00. The firm currently has an underweight rating on the stock.

Rocket Companies (NYSE:RKT) had its price target boosted by Morgan Stanley from $16.00 to $18.00. Morgan Stanley currently has an equal weight rating on the stock.

Sensata Technologies (NYSE:ST) had its target price raised by The Goldman Sachs Group, Inc. from $40.00 to $44.00. They currently have a buy rating on the stock.

Synchrony Financial (NYSE:SYF) had its price target raised by Morgan Stanley from $72.00 to $82.00. Morgan Stanley currently has an equal weight rating on the stock.

Zions Bancorporation, N.A. (NASDAQ:ZION) had its price target raised by Morgan Stanley from $63.00 to $70.00. They currently have an equal weight rating on the stock.